News >

Real-World Data With Sipuleucel-T Showcase Promising OS in mCRPC

Gina Columbus
Published: Wednesday, Sep 04, 2019

Celestia S. Higano, MD, FACP, professor, Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center

Celestia S. Higano, MD, FACP

Sipuleucel-T (Provenge) was associated with a median overall survival (OS) of 47.7 months in patients with asymptomatic or minimally invasive metastatic castration-resistant prostate cancer (mCRPC) when their baseline prostate-specific antigen (PSA) was ≤5.27 ng/mL, according to real-world results of the PROCEED registry that were published in Cancer.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication